


JC10 Rec'd PCT/PTO 2 5 JAN 2002

FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 15280-4003US	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Unknown 10/048072	
INTERNATIONAL APPLICATION NO. PCT/US00/20641		INTERNATIONAL FILING DATE 27 July 2000		PRIORITY DATE CLAIMED 28 July 1999; 28 January 2000; 28 April 2000	
TITLE OF INVENTION IMMUNOTHERAPY IN HIV INFECTED PERSONS USING VACCINES AFTER MULTI-DRUG TREATMENT					
APPLICANT(S) FOR DO/EO/US FRANCHINI, Genoveffa; HEL, Zdenek; SHEARER, Gene; TARTAGLIA, James; NACSA, Janos					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 36 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 37(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 36 U.S.C. 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information:					
EXPRESS MAIL NO. 827032437US; Declarations and Powers of Attorney of Genoveffa Franchini, Zdenek Hel, Gene Shearer, James Tartaglia, Janos Nacsa; Appointment of Associate Attorneys and Agents; Statement under 37 C.F.R. §3.73(b); Change of Correspondence Address; and Return Receipt Postcard.					

10048072-012502

I/S/ Application No. (if known, see 37 CFR 1.53) Unknown 107048072		INTERNATIONAL APPLICATION NO. PCT/US00/20641		ATTORNEY'S DOCKET NUMBER 15280-4003US																					
21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY																					
BASIC NATIONAL FEE (37 CFR 1.492(A) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.492) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1040.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but International Search report prepared by the EPO of JPO\$890.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$740.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)(4)\$100.00 <div style="text-align: right;"> ENTER APPROPRIATE BASIC FEE AMOUNT = </div>																									
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).																									
<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:20%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> <th style="width:20%;">\$</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>17 - 20 =</td> <td>0</td> <td>x \$18.00</td> <td>\$</td> </tr> <tr> <td>Independent claims</td> <td>1 - 3 =</td> <td>0</td> <td>x \$84.00</td> <td>\$</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ 280.00 \$</td> </tr> </tbody> </table>						CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	17 - 20 =	0	x \$18.00	\$	Independent claims	1 - 3 =	0	x \$84.00	\$	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ 280.00 \$
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			\$																			
Total claims	17 - 20 =	0	x \$18.00	\$																					
Independent claims	1 - 3 =	0	x \$84.00	\$																					
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ 280.00 \$																					
TOTAL OF ABOVE CALCULATIONS =																									
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$																					
SUBTOTAL =				\$890.00																					
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFT 1.492(f)).				\$																					
TOTAL NATIONAL FEE =				\$890.00																					
Fee for recording the enclosed assignment (37 CFR 1.2(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$40.00																					
TOTAL FEES ENCLOSED =				\$930.00																					
				Amount to be refunded: \$																					
				charged: \$																					
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>20-1430</u> in the amount of \$ <u>930.00</u> to cover the above fees. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>20-1430</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.																									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.																									
SEND ALL CORRESPONDENCE TO: Jean M. Lockyer Townsend and Townsend and Crew LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834																									
				 SIGNATURE																					
				<u>Jean M. Lockyer</u> NAME																					
				<u>44,879</u> REGISTRATION NUMBER																					

205270-048072

PATENT

Attorney Docket No. 015280-400300US

DHHS Ref. No. E-212-99/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Examiner: Unassigned
)	
FRANCHINI <i>et al.</i>)	Art Unit: Unassigned
)	
Application No.: Unassigned)	<u>CHANGE OF CORRESPONDENCE</u>
)	<u>ADDRESS ACCORDING TO</u>
Filed: Herewith)	<u>MPEP 403(a) and 403.01</u>
)	
For: IMMUNOTHERAPY IN HIV)	
INFECTED PERSONS USING VACCINES)	
AFTER MULTI-DRUG TREATMENT)	

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

Please address all future correspondence in this case to:

Jean M. Lockyer
TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834

Telephone: (415) 576-0200
Facsimile: (415) 576-0300

Dated: 1/11/2002

Respectfully submitted,

United States Department of Health and Human
Services

By D. D. B. B.

Reg. No.: 42,319
Office of Technology Transfer
National Institutes of Health
6011 Executive Boulevard, Suite 325
Rockville, Maryland 20852
Telephone: (301) 496-7056